Carson Wealth (CWM LLC)
KNTE

Carson Wealth (CWM LLC)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80
Closed -$1K – 4321
2022
Q3 		$1K Hold
80
– – ﹤0.01% 3833
2022
Q2 		$1K Buy
+80
New +$745 ﹤0.01% 3705

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Carson Wealth (CWM LLC)'s KNTE Position: Q4 2022 in Review

Carson Wealth (CWM LLC) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 80 shares — an estimated $1K sold.

Carson Wealth (CWM LLC) first reported a position in KNTE in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Carson Wealth (CWM LLC) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 80 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • Carson Wealth (CWM LLC) first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Carson Wealth (CWM LLC)'s Kinnate Biopharma Inc. Common Stock position peaked at $1K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q4 2022, filed 1 Feb 2023.